Therapeutic Options in High-risk Non-muscle-invasive Bladder Cancer During the Current Worldwide Shortage of Bacille Calmette-Guerin

被引：61
|
作者：
Mostafid, A. Hugh [1 ]
Palou Redorta, Joan [2 ]
Sylvester, Richard [3 ]
Witjes, J. Alfred [4 ]
机构：
[1] Royal Surrey Cty Hosp, Dept Urol, Guildford, Surrey, England
[2] Univ Autonoma Barcelona, Dept Urol, Fundacio Puigvert, E-08193 Barcelona, Spain
[3] European Org Res Treatment Canc, Brussels, Belgium
[4] Radboud UMC, Dept Urol, Nijmegen, Netherlands
来源：
EUROPEAN UROLOGY | 2015年 / 67卷 / 03期
关键词：
TRANSITIONAL-CELL CARCINOMA; IMMUNOTHERAPY; MAINTENANCE; T1; TA;
D O I：
10.1016/j.eururo.2014.11.031
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：359 / 360
页数：2
相关论文
共 50 条
  • [41] Contemporary Cost-Effectiveness Analysis Comparing Sequential Bacillus Calmette-Guerin and Electromotive Mitomycin Versus Bacillus Calmette-Guerin Alone for Patients With High-Risk Non-Muscle-Invasive Bladder Cancer
    Bachir, Bassel G.
    Dragomir, Alice
    Aprikian, Armen G.
    Tanguay, Simon
    Fairey, Adrian
    Kulkarni, Girish S.
    Breau, Rodney H.
    Black, Peter C.
    Kassouf, Wassim
    CANCER, 2014, 120 (16) : 2424 - 2431
  • [42] Intravesical Bacillus Calmette-Guerin with interferon-alpha versus intravesical Bacillus Calmette-Guerin for treating non-muscle-invasive bladder cancer
    Shepherd, Andrew R. H.
    Shepherd, Emily
    Brook, Nicholas R.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (03):
  • [43] Clinical management of high-risk non-muscle-invasive bladder cancer during BCG shortage: what are the options, what are the risks?
    Burger, Maximilian
    AKTUELLE UROLOGIE, 2020, 51 (04) : 344 - 347
  • [44] Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guerin failure
    Shantharam, Govind
    Amin, Ali
    Pereira, Jorge
    Kott, Ohad
    Mueller-Leonhard, Catrina
    Mega, Anthony
    Golijanin, Dragan
    Gershman, Boris
    CURRENT UROLOGY, 2021, 15 (01) : 33 - 38
  • [45] Bacillus Calmette-Guerin (BCG) and alternatives Drug treatment of high-risk non-muscle invasive bladder cancer
    Leucht, K.
    Foller, S.
    Grimm, Marc-Oliver
    UROLOGE, 2021, 60 (11): : 1400 - 1408
  • [46] THE BURDEN OF HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER AMONG PATIENTS TREATED WITH BACILLUS CALMETTE-GUERIN
    Kopenhafer, L.
    Chang, J.
    Thompson, A.
    Sikirica, S.
    Masters, E. T.
    Cappelleri, J. C.
    Peck, E. Y.
    Maculaitis, M. C.
    VALUE IN HEALTH, 2022, 25 (07) : S557 - S557
  • [47] Outcomes of bacillus Calmette-Guerin therapy without a maintenance schedule for high-risk non-muscle-invasive bladder cancer in the second transurethral resection era
    Kikuchi, Hiroshi
    Abe, Takashige
    Matsumoto, Ryuji
    Osawa, Takahiro
    Maruyama, Satoru
    Murai, Sachiyo
    Shinohara, Nobuo
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (03) : 251 - 258
  • [48] Maintenance Bacillus Calmette-Guerin Treatment of Non-muscle-invasive Bladder Cancer: A Critical Evaluation of the Evidence
    Ehdaie, Behfar
    Sylvester, Richard
    Herr, Harry W.
    EUROPEAN UROLOGY, 2013, 64 (04) : 579 - 585
  • [49] Smoking Reduces the Efficacy of Intravesical Bacillus Calmette-Guerin Immunotherapy in Non-muscle-invasive Bladder Cancer
    Rink, Michael
    Xylinas, Evanguelos
    Babjuk, Marko
    Pycha, Armin
    Karakiewicz, Pierre I.
    Novara, Giacomo
    Dahlem, Roland
    Shariat, Shahrokh F.
    EUROPEAN UROLOGY, 2012, 62 (06) : 1204 - 1206
  • [50] Renal Granulomatosis Post Intravesical Bacillus Calmette-Guerin Therapy for Non-muscle-invasive Bladder Cancer
    Tran-Harding, Karen
    Nair, Rashmi T.
    Ganesh, Halemane
    JOURNAL OF CLINICAL IMAGING SCIENCE, 2018, 8
12345